Moderna Inc (MRNA)
$122.50
1.36 (1.12%)
MRNA Stock Quote Delayed 30 Minutes
Covid-19 Simplifies Things for Moderna Investors
The price of MRNA stock is now entirely determined by the path of the COVID-19 pandemic. Early investors should take this as a cue to exit.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
46.92B
PE Ratio
-7.82
EPS
-15.66
Volume (Avg. Vol.)
1.81M
Day's Range
$120.44 - $124.06
52-Week Range
$62.55 - $170.47
Dividend & Yield
N/A (N/A)
MRNA Stock Predictions, Articles, and Moderna Inc News
Moderna Stock Could Have a Lot Further to Fall After Disasterous Earnings
Over the last five trading sessions, Moderna's stock has cratered 30%, dropping from $350 a share all the way down to $240. The steep fall came after the Cambridge, Massachusetts-based company reported disappointing quarterly results that shocked Wall Street and revised down its forward guidance.
Moderna’s Outlook Is Directly Tied to the Eventual Receding of Covid-19
With Covid-19 receding and a one-dimensional product pipeline, MRNA stock is a one-trick-pony without any long-term prospects.
Recent Weakness May Mean Opportunity With Moderna Stock
If you already own MRNA stock, it's too early to sell. If you do not yet own it? It's not too late to buy.
Moderna Stock Looks Fully Valued Here, But It Has a Great Future
Moderna has a host of vaccines in its pipeline, including against cancer and HIV. It's not a one-trick pony.
Once-Cinderella Novavax Stock Could Be Poisoned by Merck’s Covid Pill
With a new oral antiviral drug by Merck potentially over the horizon, NVAX stock may be trading on borrowed time.
Accept Volatility in Moderna As It Should Prevail in Time
There's no need to abandon MRNA stock now as Moderna remains an aggressive pioneer in advancing mRNA therapeutics.
4 Top Stock Trades for Monday: BTC, ETH, NVAX, MRNA
Bitcoin, Ethereum, Novavax and Moderna were our top stock trades for Monday. Now, let's look at how the charts are setting up for next week.
Vaccine Stocks: Why MRNA, VXRT, CVAC and NVAX Stocks Need a Band-Aid Today
Today, vaccine stocks are taking a massive hit as investors price in the potential effect of oral medications for Covid-19 on this sector.
Moderna Has Ripped Through Analyst Estimates This Year, and Might Not Stop
Moderna has blasted through analysts' earnings this year and might keep doing that. FCF could end up much more than analysts foresee next year, pushing MRNA stock 44% higher to $618 per share.
What Did the Stock Market Do Today, Aug. 23? 3 Big Stories to Catch Up On.
So what did the stock market do today? Investors cheered on Pfizer stock and rallied behind infrastructure plays.
4 Top Stock Trades for Tuesday: PFE, MRNA, NVDA, BABA
Pfizer, Moderna, Nvidia and Alibaba were our top stock trades for Tuesday. Now, let's get a look at the charts as the market hits new highs.
What Did the Stock Market Do Today, Aug. 11? 3 Big Stories to Catch Up On.
So what did the stock market do today? All eyes were on earnings reports from POSH, WIX and PRGO in an odd pandemic world.
